Annabel Samimy

Stock Analyst at Stifel

(3.50)
# 893
Out of 5,038 analysts
49
Total ratings
45.65%
Success rate
34.53%
Average return

Stocks Rated by Annabel Samimy

Palvella Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $60$80
Current: $73.32
Upside: +9.11%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $26.66
Upside: +87.55%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.90
Upside: +361.54%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20$17
Current: $5.35
Upside: +217.76%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $14.78
Upside: +170.64%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $6.80
Upside: +164.71%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $13.46
Upside: +78.31%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $12.19
Upside: +228.14%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $31.42
Upside: +154.61%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225$230
Current: $138.52
Upside: +66.04%
Reiterates: Buy
Price Target: $23$25
Current: $6.82
Upside: +266.57%
Initiates: Buy
Price Target: $35
Current: $21.20
Upside: +65.09%
Maintains: Buy
Price Target: $60$65
Current: $28.14
Upside: +130.99%
Downgrades: Hold
Price Target: $700$275
Current: $11.18
Upside: +2,359.75%
Initiates: Buy
Price Target: $45
Current: $42.04
Upside: +7.04%
Upgrades: Buy
Price Target: $120
Current: $3.77
Upside: +3,083.02%
Initiates: Buy
Price Target: $24
Current: $2.42
Upside: +893.79%
Maintains: Buy
Price Target: $700$750
Current: $1.22
Upside: +61,375.41%
Maintains: Hold
Price Target: $25$24
Current: $50.67
Upside: -52.63%